--- title: "Parkinson's Drug Pipeline 2026: Experimental Treatments by Stage" description: "A plain-language, regularly-updated tracker of experimental Parkinson's drugs and therapies, grouped by development stage with honest caveats." canonical_url: "https://parkinsonspathways.com/pipeline" last_updated: 2026-06-01 source: "Parkinson's Pathways" --- # Parkinson's Drug Pipeline A plain-language overview of the experimental Parkinson's drugs and therapies we are tracking, grouped by how far along they are in testing. Most treatments that enter human trials never reach patients, and even approved new drugs are usually better ways to deliver existing medicines rather than cures. We flag what is and isn't proven, and we treat company press releases as a starting point, not the final word. _Last reviewed: 2026-06-01._ **At a glance:** 15 treatments tracked · 8 in Phase 3 or approved · 4 new this update · 3 recently failed. ## Recently approved Cleared by the FDA and available by prescription. New approvals are almost always better ways to deliver existing medicines, not cures. - [Foslevodopa/foscarbidopa (Vyalev (Produodopa in Europe))](https://parkinsonspathways.com/pipeline/vyalev-foslevodopa-foscarbidopa), A 24-hour under-the-skin infusion of levodopa, FDA-approved in 2024 for advanced Parkinson's. It steadies medication levels but does not slow the disease. - [Carbidopa/levodopa extended-release capsules (Crexont)](https://parkinsonspathways.com/pipeline/crexont-extended-release-carbidopa-levodopa), An extended-release levodopa pill, FDA-approved in 2024, designed to be taken fewer times a day. It is a convenience improvement, not a disease-slowing drug. ## Phase 3: large human trials Being tested in large groups (often hundreds to thousands of people) to confirm whether they actually help and are safe enough to approve. This is the last stage before a company can apply to the FDA. - [Tavapadon](https://parkinsonspathways.com/pipeline/tavapadon), An experimental once-daily pill that targets dopamine D1/D5 receptors. Its Phase 3 TEMPO program reported meeting its main goals; it is a symptom treatment, not disease-modifying. - [Buntanetap](https://parkinsonspathways.com/pipeline/buntanetap), An oral candidate aimed at reducing several nerve-damaging proteins at once. Company-reported Phase 3 results in early Parkinson's are mixed, and independent peer-reviewed data are still limited. - [Prasinezumab](https://parkinsonspathways.com/pipeline/prasinezumab), An antibody aimed at the alpha-synuclein protein, being tested to see if it can slow Parkinson's. Results so far are mixed and not yet conclusive. - [Ambroxol](https://parkinsonspathways.com/pipeline/ambroxol), A repurposed cough medicine being tested as a possible disease-modifier, with special interest in people who carry a GBA gene variant. - [BIIB122 (LRRK2 inhibitor)](https://parkinsonspathways.com/pipeline/biib122-lrrk2-inhibitor), A pill targeting the LRRK2 enzyme, in large trials to test whether it can slow Parkinson's. Results are not yet available. - [Bemdaneprocel (stem-cell-derived neurons)](https://parkinsonspathways.com/pipeline/bemdaneprocel-cell-therapy), An experimental cell transplant that places lab-grown dopamine neurons into the brain. Early safety results were encouraging; a larger trial is planned. ## Phase 2: mid-stage testing Tested in smaller groups to look for early signs of benefit and the right dose. Encouraging Phase 2 results often do not hold up in Phase 3. - [Lixisenatide](https://parkinsonspathways.com/pipeline/lixisenatide-glp1), A repurposed diabetes drug tested to see if it slows Parkinson's. A Phase 2 trial found a small slowing of symptom worsening, alongside notable nausea. - [Minzasolmin](https://parkinsonspathways.com/pipeline/minzasolmin), An oral drug aimed at preventing alpha-synuclein from clumping, in a Phase 2 trial. Whether it slows Parkinson's is not yet known. - [Terazosin (and related repurposed blood-pressure drugs)](https://parkinsonspathways.com/pipeline/terazosin-repurposed), Repurposed blood-pressure medicines being explored as possible disease-modifiers. The evidence is mostly from health-record databases and small studies, intriguing but far from proven. ## Phase 1: first human safety tests The earliest human studies, focused on safety rather than whether the treatment works. - [AB-1005 (GDNF gene therapy)](https://parkinsonspathways.com/pipeline/ab-1005-gdnf-gene-therapy), An experimental one-time brain gene therapy designed to deliver a nerve-protecting growth factor (GDNF). It is in early safety testing; whether it helps is unknown. ## Recently stopped or failed Programs that recently failed a major trial or were halted. We keep them here because understanding what didn't work is part of an honest picture of the research. - [Exenatide](https://parkinsonspathways.com/pipeline/exenatide-pd3), A repurposed diabetes drug that raised hopes after a small earlier study, but failed to slow Parkinson's in a larger Phase 3 trial reported in 2024. - [Cinpanemab](https://parkinsonspathways.com/pipeline/cinpanemab), An anti–alpha-synuclein antibody that failed its Phase 2 trial in 2021 and was discontinued. Included for an honest picture of the field. - [Venglustat](https://parkinsonspathways.com/pipeline/venglustat), A drug aimed at GBA-related Parkinson's that failed its Phase 2 trial in this group and was not advanced for Parkinson's. Included for an honest picture. ## Related - [Browse all recruiting trials](https://parkinsonspathways.com/trials) - [Match yourself to relevant trials](https://parkinsonspathways.com/match) - [How to spot a questionable clinical trial](https://parkinsonspathways.com/learn/how-to-spot-a-questionable-clinical-trial)